Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS231295 in Advanced Solid Tumors
NCT06902350Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS231295 in solid tumor (advanced stage), small cell lung cancer (SCLC) and glioblastoma (GBM), sponsored by Akeso, Inc. Primary endpoints: Incidence of Dose-Limiting Toxicity at 34 days, Maximum Tolerated Dose at 2 years and 4 more. Started May 2025; status: recruiting.
02
Drugs
CS231295
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06902350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902350.